South Africa will pause its rollout of the AstraZeneca COVID-19 vaccine after a small study suggested it offers minimal protection against mild and moderate infection from the South African coronavirus strain known as B.1.351.
The analysis is yet to be peer reviewed or published.
Work is already underway at the University of Oxford and in conjunction with partners to produce a second generation of the vaccine which has been adapted to target variants of the coronavirus with mutations similar to B.1.351, if it should prove necessary to do so.
South Africa has paused AstraZeneca COVID vaccine rollout but it's too early to say Australia should follow suit (theconversation.com)
